Search Results

You are looking at 261 - 270 of 524 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification

Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou, and Shu-Jen Chen

Regan MM Maiorano E . Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 . J

Full access

Defining Cancer Care Quality or Delivering Quality Cancer Care?

Matt Brow, J. Russell Hoverman, Debra Patt, Bill Herman, Diana Verrilli, Jody Garey, and Roy Beveridge

support (and your adopted pathway for any given instance) when it really matters—at the point of decision—can be expensive. Agreement on common definitions can also be difficult, even for elements as simple as what constitutes third-line or adjuvant

Full access

Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations

Gayathri Nagaraj and Cynthia X. Ma

. Describe the ideal treatment with adjuvant chemotherapy for patients with estrogen receptor (ER)-positive HER2-negative lymph node-negative breast cancer. Case Report A 67-year-old otherwise healthy postmenopausal woman presented for adjuvant

Full access

Cervical Cancer

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Robert L. Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, Mark A. Morgan, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole R. McMillian, and Miranda Hughes

with cervical cancer either as 1) definitive therapy for those with locally advanced disease or for those who are poor surgical candidates, or 2) adjuvant therapy after radical hysterectomy for those who have one or more pathologic risk factors (eg

Full access

Optimal Treatment of Unresectable Nonmelanoma Skin Cancers

Thomas Olencki

.” Furthermore, “vismodegib may be considered for neoadjuvant therapy, but there is no role for it as adjuvant therapy at this time,” concluded Dr. Olencki. New Agents Are Needed for MCC Considered to be one of the most lethal skin cancers, MCC is an

Full access

The NCCN Guidelines Program and Opportunities for Quality Improvement

Stephen B. Edge

surgery to adjuvant therapies, as defined by the NCCN Oncology Outcomes Database. 21 , 22 Time to treatment may be an important measure of the performance of a cancer program. Delays in treatment, and disparities in delay have clearly been described in

Full access


risks of postsurgical complications. 5 “How we thought about adjuvant therapy has changed,” said Dr. Gradishar. “Physicians used to look at the number of nodes as a determinant of whether a patient was a candidate for chemotherapy, as well as what kind

Full access

Clinical Treatment Decisions for Advanced Renal Cell Cancer

Toni K. Choueiri

, they should not be given outside of a clinical trial, Dr. Choueiri noted. Numerous biomarkers are under investigation, but none should be clinically applied at this time, he said. Adjuvant Therapy and Other Histologies In contrast to metastatic

Full access

Dermatofibrosarcoma Protuberans

Stanley J. Miller, Murad Alam, James S. Andersen, Daniel Berg, Christopher K. Bichakjian, Glen M. Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Alan L. Ho, Anne Kessinger, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, Ashok R. Shaha, Malika Tuli, Marshall M. Urist, Linda C. Wang, and John A. Zic

with cytogenetics may be useful before initiating imatinib therapy. Radiation has occasionally been used as a primary therapeutic modality for DFSP, 35 but it is more commonly used as adjuvant therapy after surgery. 36 – 38 Postoperative radiation

Full access

Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib

Joshua B. Brown, Reetesh K. Pai, Melissa A. Burgess, Jennifer Chennat, and Amer H. Zureikat

for borderline resectable GIST . J Natl Compr Canc Netw 2012 ; 10 : 1477 – 1482 ; quiz 1482 . 6. Corless CL Ballman KV Antonescu CR . Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected